Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples